Is there a benefit in treating novel corona virus (Sars-CoV2) infections with the established antihypertensive valsartan?

Phase 1

• Conditions: Sars-Cov2 infection; Therapeutic area: Diseases [C] - Virus Diseases [C02]

• Registration Number: EUCTR2020-001431-27-DE
• Lead Sponsor: Klinikum St. Georg gGmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-04-07
• Last Update Posted: 21 June 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

- Patients aged over 18 years with given consent, first positive Sars-Cov2 detection within the last three days
- Patients with pre-existing chronic renal insufficiency in any degree of severity
- Patients of both gender
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 200
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 100

Exclusion Criteria

- intolerance to RAS-I and ARB
- Contraindications against ACE/ARB according to current clinical standard
- History of falls (more than 2 falls in the last 8 weeks)
- Symptomatic hypotension (i.e. blood pressure < 100 mmHg systolic and/or 50 mmHg diastolic together with hypotensive symptoms)
- Acute renal failure from stage 2
- pregnancy

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified